Clinical trials: Psychological Disorders
Major Depressive Disorder
Oral Multiple-dose Study in Patients With Major Depressive Disorder
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
- Trial name
- NCT01924520
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Primary Progressive Nonfluent Aphasia
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
- Trial name
- AIDA (NCT03174886)
- Testing
- AADvac1 40 µg, AADvac1 160 µg
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Axon Neuroscience SE
Insomnia
Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia
Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep.
- Trial name
- NCT05840822
- Testing
- Cannabidiol (CBD) Capsule 75mg
- Where
- 5 sites in Australia
- Volunteers
- 519 people
- Sponsor
- Avecho Biotechnology
Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective…
- Trial name
- NCT01941043
- Testing
- CERC-301
- Where
- 24 sites in United States
- Volunteers
- 1,357 people
- Sponsor
- Avalo Therapeutics, Inc.
Alzheimer Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
- Trial name
- NCT05575076
- Testing
- Simufilam
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 1,081 people
- Sponsor
- Cassava Sciences, Inc.
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058013
- Testing
- NMRA-335140
- Where
- 74 sites in United States, Brazil and 2 more
- Volunteers
- 430 people
- Sponsor
- Neumora Therapeutics, Inc.
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Sleep Quality, Quality of Lifte
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Improving Sleep in Visually Impaired Patients
Trial title: Effectiveness of Electrical Vestibular Nerve Stimulation in the Improvement of Sleep in Patients with Visual Impairment.
- Conditions
- Sleep Quality, Quality of Lifte, Non-24 Sleep-Wake Disorder
- Trial name
- NCT06956118
- Testing
- Intervention (VeNS Stimulation) Device
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Substance Use Disorder (SUD), Anxiety Disorder Generalized
Mindfulness-Based Psychoeducation With Substance Use and Anxiety Disorders
This observational study evaluated a structured mindfulness-based psychoeducation program focused on emotional awareness, forgiveness, and self-awareness to reduce anxiety and support recovery from substance use in adults.
- Trial name
- MBPASA (NCT07483918)
- Testing
- Mindfulness-Based Psychoeducation Program
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bout Me Healing
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression in America Latina
The purpose of this study is to estimate the prevalence of Treatment Resistant Depression (TRD) among Major Depressive Disorder (MDD) participants being treated in a psychiatry reference site (example, clinic, ambulatory…
- Trial name
- TRAL (NCT03207282)
- Where
- 33 sites in Argentina, Brazil and 2 more
- Volunteers
- 1,539 people
- Sponsor
- Janssen-Cilag, S.A.
Autism Spectrum Disorder
Double Blind Trial in Children With Autism Spectrum Disorder
This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo
- Trial name
- NCT06058962
- Testing
- Suramin Sodium
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Paxmedica
Pain, Chronic Pain
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
The purpose of this study is to evaluate the impact of genetic testing on healthcare decisions and patient outcomes for patients suffering from pain, cardiovascular problems, Arthritis, Type II Diabetes, and/or Mental Health…
- Conditions
- Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases
- Trial name
- REVOLUTION (NCT02487888)
- Testing
- Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
- Where
- 31 sites in United States
- Volunteers
- 100,000 people
- Sponsor
- Proove Bioscience, Inc.
Lewy Body Dementia, Non-DLB Dementia
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical…
- Conditions
- Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia
- Trial name
- NCT00209456
- Testing
- DatSCAN
- Where
- Germany
- Volunteers
- 326 people
- Sponsor
- GE Healthcare
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Schizophrenia, Cerebellar Ataxia
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK) of single and multiple rising doses of TAK-831 in healthy participants.
- Trial name
- NCT02566759
- Testing
- TAK-831 Oral Suspension, TAK-831 Tablet
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Disorder
40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
Bipolar disorder is characterized by mood swings that range from from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159783
- Testing
- asenapine, Olanzapine
- Volunteers
- 218 people
- Sponsor
- Organon and Co
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.